- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Vivimed labs gets Uzbekistan Govt nod for Orzole combi, Bilastin tablets
Hyderabad: Vivimed Labs Limited has recently announced that the company has received approval for 2 products from Uzbekistan Government for its PICS & Health Canada approved site, both facilities are situated at Hyderabad
1. PRODUCT: Bilastin tablets( Brand Name FLUSTIN)- is a second-generation antihistamine (a selective histamine Hi receptor antagonist
USES: It is used in the treatment of allergic Rhino conjunctivitis and Urticaria (hives).
2. PRODUCT: Orzole combi
USES: Ofloxacin + Ornidazole is used in the treatment of bacterial & parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections
Commenting on the Approval, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "We are very excited to receive approval to Vivimed's own products. Vivimed strategy is to increase its share of Branded products in CIS Markets. Vivimed shall be launching these products in 2021. Our purpose is to offer innovative & top quality formulations at affordable prices. This approval is testimony to Vivimed's growth strategy"
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751